These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 34248944)

  • 1. Something Old, Something New: Ion Channel Blockers as Potential Anti-Tuberculosis Agents.
    Mitini-Nkhoma SC; Chimbayo ET; Mzinza DT; Mhango DV; Chirambo AP; Mandalasi C; Lakudzala AE; Tembo DL; Jambo KC; Mwandumba HC
    Front Immunol; 2021; 12():665785. PubMed ID: 34248944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ion Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosis.
    Machado D; Pires D; Perdigão J; Couto I; Portugal I; Martins M; Amaral L; Anes E; Viveiros M
    PLoS One; 2016; 11(2):e0149326. PubMed ID: 26919135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
    Kiran D; Podell BK; Chambers M; Basaraba RJ
    Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial efflux pumps and Mycobacterium tuberculosis drug tolerance: evolutionary considerations.
    Szumowski JD; Adams KN; Edelstein PH; Ramakrishnan L
    Curr Top Microbiol Immunol; 2013; 374():81-108. PubMed ID: 23242857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered drug efflux under iron deprivation unveils abrogated MmpL3 driven mycolic acid transport and fluidity in mycobacteria.
    Pal R; Hameed S; Fatima Z
    Biometals; 2019 Feb; 32(1):49-63. PubMed ID: 30430296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host- Directed Therapies.
    Borah P; Deb PK; Venugopala KN; Al-Shar'i NA; Singh V; Deka S; Srivastava A; Tiwari V; Mailavaram RP
    Curr Top Med Chem; 2021; 21(6):547-570. PubMed ID: 33319660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host-Pathogen Interaction as a Novel Target for Host-Directed Therapies in Tuberculosis.
    Abreu R; Giri P; Quinn F
    Front Immunol; 2020; 11():1553. PubMed ID: 32849525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Tuberculosis Antimicrobials on the Immunometabolic Profiles of Primary Human Macrophages Stimulated with
    Cahill C; Cox DJ; O'Connell F; Basdeo SA; Gogan KM; Ó'Maoldomhnaigh C; O'Sullivan J; Keane J; Phelan JJ
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multidrug efflux protein in Mycobacterium tuberculosis; tap as a potential drug target for drug repurposing.
    Dwivedi M; Mukhopadhyay S; Yadav S; Dubey KD
    Comput Biol Med; 2022 Jul; 146():105607. PubMed ID: 35617724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics.
    Hawn TR; Shah JA; Kalman D
    Immunol Rev; 2015 Mar; 264(1):344-62. PubMed ID: 25703571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug permeation and metabolism in Mycobacterium tuberculosis: Prioritising local exposure as essential criterion in new TB drug development.
    Tanner L; Denti P; Wiesner L; Warner DF
    IUBMB Life; 2018 Sep; 70(9):926-937. PubMed ID: 29934964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efflux pump inhibitors as a promising adjunct therapy against drug resistant tuberculosis: a new strategy to revisit mycobacterial targets and repurpose old drugs.
    Rodrigues L; Cravo P; Viveiros M
    Expert Rev Anti Infect Ther; 2020 Aug; 18(8):741-757. PubMed ID: 32434397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposing Tamoxifen as Potential Host-Directed Therapeutic for Tuberculosis.
    Boland R; Heemskerk MT; Forn-Cuní G; Korbee CJ; Walburg KV; Esselink JJ; Carvalho Dos Santos C; de Waal AM; van der Hoeven DCM; van der Sar E; de Ries AS; Xie J; Spaink HP; van der Vaart M; Haks MC; Meijer AH; Ottenhoff THM
    mBio; 2023 Feb; 14(1):e0302422. PubMed ID: 36475748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of new antituberculous drugs based on bacterial virulence factors interfering with host cytokine networks.
    Tomioka H; Tatano Y; Sano C; Shimizu T
    J Infect Chemother; 2011 Jun; 17(3):302-17. PubMed ID: 21243398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting redox heterogeneity to counteract drug tolerance in replicating
    Mishra R; Kohli S; Malhotra N; Bandyopadhyay P; Mehta M; Munshi M; Adiga V; Ahuja VK; Shandil RK; Rajmani RS; Seshasayee ASN; Singh A
    Sci Transl Med; 2019 Nov; 11(518):. PubMed ID: 31723039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.